← Leaderboards
Cecilia C Cheng-Mayer
Aaron Diamond Aids Research Center
$25,693,681
Attributed
$26,737,977
Total exposure
45
Grants
35
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–15$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$26,737,977 · 45
By mechanism
R01$16,861,731 · 6
R37$5,006,786 · 1
P51$2,168,066 · 34
R24$1,702,263 · 1
R56$748,758 · 1
R21$250,373 · 1
Top collaborators
- Martin H Markowitz2 shared
Most similar at Aaron Diamond Aids Research Center
Same institution · by research overlap
- Janet M Harouse$2,203,334
- David D Ho$21,580,589
- Melissa E Kane$2,717,345
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaMacacaHiv-1InfectionVirusSimian Human Immunodeficiency VirusSourceResourcesTransmission ProcessResearch PersonnelFundingGrantAnimalsIn VivoUnited States National Institutes Of HealthPathogenesisViralBaseCcr5 GeneInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseDoseCellsSimian Immunodeficiency Virus
Grant awards (77)
Generation of Genotypically Diverse R5 SHIVs as Tools in HIV-1 Vaccine Research$865,415
R24 · FY2015 · AI · contact PI
Generation of Genotypically Diverse R5 SHIVs as Tools in HIV-1 Vaccine Research$836,848
R24 · FY2014 · AI · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$1,591,251
R01 · FY2013 · AI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$748,758
R56 · FY2013 · AI · contact PI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$1,104,451
R01 · FY2012 · AI · contact PI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$497,342
R01 · FY2012 · AI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$767,830
R01 · FY2011 · AI · contact PI
R5 SHIV/MACAQUE MODEL FOR THE EVALUATION OF T AND B CELL-BASED HIV-1 VACCINE$57,750
P51 · FY2011 · RR · contact PI
ASSESSMENT OF VACCINE/MICROBICIDE COMBINATION EFFICACY IN THE MACAQUE MODEL$57,750
P51 · FY2011 · RR · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$57,750
P51 · FY2011 · RR · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$57,750
P51 · FY2011 · RR · contact PI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$869,155
R01 · FY2010 · AI · contact PI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$609,311
R37 · FY2010 · AI · contact PI
Assessment of vaccine/microbicide combination efficacy in the macaque model$507,283
R01 · FY2010 · AI · contact PI
REFINEMENT OF THE SHIV/MACAQUE MODEL FOR ASSESSMENT OF CANDIDATE MICROBICIDES$61,801
P51 · FY2010 · RR · contact PI
COMBINATION VACCINE/MICROBICIDE EFFICACY ASSESSMENT IN THE SHIV/MACAQUE MODEL$61,801
P51 · FY2010 · RR · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$61,801
P51 · FY2010 · RR · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$61,801
P51 · FY2010 · RR · contact PI
IN VIVO SAFETY AND EFFICACY OF CAP FILM AND MICROBICIDE COMBINATIONS$61,801
P51 · FY2010 · RR · contact PI
R5 SHIV/MACAQUE MODEL FOR THE EVALUATION OF T AND B CELL-BASED HIV-1 VACCINE$61,801
P51 · FY2010 · RR · contact PI
Assessment of vaccine/microbicide combination efficacy in the macaque model$1,280,247
R01 · FY2009 · AI · contact PI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$897,508
R01 · FY2009 · AI · contact PI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$597,537
R37 · FY2009 · AI · contact PI
Transmission & Pathogenesis of X4 & R5 SHIVs$539,078
R01 · FY2009 · AI · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$62,691
P51 · FY2009 · RR · contact PI
REFINEMENT OF THE SHIV/MACAQUE MODEL FOR ASSESSMENT OF CANDIDATE MICROBICIDES$62,691
P51 · FY2009 · RR · contact PI
IN VIVO SAFETY AND EFFICACY OF CAP FILM AND MICROBICIDE COMBINATIONS$62,691
P51 · FY2009 · RR · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$62,691
P51 · FY2009 · RR · contact PI
COMBINATION VACCINE/MICROBICIDE EFFICACY ASSESSMENT IN THE SHIV/MACAQUE MODEL$62,691
P51 · FY2009 · RR · contact PI
Assessment of vaccine/microbicide combination efficacy in the macaque model$763,269
R01 · FY2008 · AI · contact PI
Transmission & Pathogenesis of X4 & R5 SHIVs$651,692
R01 · FY2008 · AI · contact PI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$580,136
R37 · FY2008 · AI · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$63,253
P51 · FY2008 · RR · contact PI
REFINEMENT OF THE SHIV/MACAQUE MODEL FOR ASSESSMENT OF CANDIDATE MICROBICIDES$63,253
P51 · FY2008 · RR · contact PI
COMBINATION VACCINE/MICROBICIDE EFFICACY ASSESSMENT IN THE SHIV/MACAQUE MODEL$63,253
P51 · FY2008 · RR · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$63,253
P51 · FY2008 · RR · contact PI
ENGINEERING SIMIAN-DERIVED LACTOBACILLI TO SECRETE ANTI-HIV-1 MICROBICIDES$63,253
P51 · FY2008 · RR · contact PI
IN VIVO SAFETY AND EFFICACY OF CAP FILM AND MICROBICIDE COMBINATIONS$63,253
P51 · FY2008 · RR · contact PI
Assessment of vaccine/microbicide combination efficacy in the macaque model$730,385
R01 · FY2007 · AI · contact PI
Transmission & Pathogenesis of X4 & R5 SHIVs$636,507
R01 · FY2007 · AI · contact PI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$574,144
R37 · FY2007 · AI · contact PI
Engineering Simian-derived Lactobacilli to Secrete Anti-HIV-1 Microbicides$250,373
R21 · FY2007 · AI · contact PI
REFINING THE SHIV/MACAQUE MODEL FOR ASSESSING EFFICACY OF MICROBICIDES$71,639
P51 · FY2007 · RR · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$71,638
P51 · FY2007 · RR · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$71,638
P51 · FY2007 · RR · contact PI
ANTI-HIV MICROBICIDE: CELLULOSE ACETATE$71,638
P51 · FY2007 · RR · contact PI
Transmission & Pathogenesis of X4 & R5 SHIVs$854,253
R01 · FY2006 · AI · contact PI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$574,070
R37 · FY2006 · AI · contact PI
TRANSMISSION & PATHOGENESIS OF X4 & R5 SHIVS$65,435
P51 · FY2006 · RR · contact PI
ANTI-HIV MICROBICIDE: CELLULOSE ACETATE$65,435
P51 · FY2006 · RR · contact PI
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$65,435
P51 · FY2006 · RR · contact PI
Transmission &Pathogenesis of X4 &R5 SHIVs$643,812
R01 · FY2005 · AI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$425,974
R37 · FY2005 · AI
ANTI-HIV MICROBICIDE: CELLULOSE ACETATE$56,648
P51 · FY2005 · RR
REFINEMENT OF THE SHIV/MACAQUE MODEL FOR ASSESSING EFFICACY OF MICROBICIDES$54,500
P51 · FY2005 · RR
PHENOTYPIC AND GENOTYPIC DETERMINANTS OF SHIV PATHOGENESIS$54,500
P51 · FY2005 · RR
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$54,500
P51 · FY2005 · RR
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$506,605
R01 · FY2004 · AI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$425,194
R37 · FY2004 · AI
STRUCTURE/FUNCTION RELATIONSHIP OF HIV-1$311,500
R01 · FY2004 · CA
DETERMINANTS OF SHIV PATHOGENESIS$47,161
P51 · FY2004 · RR
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$480,367
R01 · FY2003 · AI
Simian Immunodeficiency VIrus Pathogenesis$432,899
R37 · FY2003 · AI
STRUCTURE/FUNCTION RELATIONSHIP OF HIV-1$311,500
R01 · FY2003 · CA
SERIAL PASSAGE OF SHIV 162 IN JUVENILE RHESUS MACAQUES$61,560
P51 · FY2003 · RR
MUCOSAL TRANSMISSION OF SIMIAN-HUMAN IMMUNODEFICIENCY$61,560
P51 · FY2003 · RR
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$568,926
R01 · FY2002 · AI
Simian Immunodeficiency VIrus Pathogenesis$428,421
R37 · FY2002 · AI
STRUCTURE/FUNCTION RELATIONSHIP OF HIV-1$311,500
R01 · FY2002 · CA
SAFETY AND EFFICACY OF CAP IN VIVO$0
P01 · FY2002 · HD
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$589,511
R01 · FY2001 · AI
Phenotypic and Genetic Determinants of SHIV Pathogenesis$359,100
R37 · FY2001 · AI
STRUCTURE/FUNCTION RELATIONSHIP OF HIV-1$311,500
R01 · FY2001 · CA
SAFETY AND EFFICACY OF CAP IN VIVO$0
P01 · FY2001 · HD
TRANSMISSION &PATHOGENESIS OF X4 &R5 SHIVS$520,921
R01 · FY2000 · AI
STRUCTURE/FUNCTION RELATIONSHIP OF HIV-1$311,500
R01 · FY2000 · CA
PHENOTYPIC AND GENETIC DETERMINANTS OF SHIV PATHOGENESIS$303,838
R01 · FY2000 · AI